JPWO2019178546A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019178546A5 JPWO2019178546A5 JP2020573089A JP2020573089A JPWO2019178546A5 JP WO2019178546 A5 JPWO2019178546 A5 JP WO2019178546A5 JP 2020573089 A JP2020573089 A JP 2020573089A JP 2020573089 A JP2020573089 A JP 2020573089A JP WO2019178546 A5 JPWO2019178546 A5 JP WO2019178546A5
- Authority
- JP
- Japan
- Prior art keywords
- gene expression
- subject
- response signature
- responsive
- tnf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 claims description 101
- 230000004044 response Effects 0.000 claims description 85
- 238000000034 method Methods 0.000 claims description 78
- 238000002560 therapeutic procedure Methods 0.000 claims description 69
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 230000004043 responsiveness Effects 0.000 claims description 25
- 229960002964 adalimumab Drugs 0.000 claims description 17
- 229960000598 infliximab Drugs 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 15
- 108010008165 Etanercept Proteins 0.000 claims description 12
- 229960000106 biosimilars Drugs 0.000 claims description 12
- 229960000403 etanercept Drugs 0.000 claims description 12
- 238000003559 RNA-seq method Methods 0.000 claims description 8
- 238000002965 ELISA Methods 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 6
- 238000002493 microarray Methods 0.000 claims description 6
- 238000003762 quantitative reverse transcription PCR Methods 0.000 claims description 6
- 238000003753 real-time PCR Methods 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 5
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 5
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 208000002557 hidradenitis Diseases 0.000 claims description 5
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims description 5
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 5
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims description 4
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 4
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims description 4
- 229960003697 abatacept Drugs 0.000 claims description 4
- 229960004238 anakinra Drugs 0.000 claims description 4
- 229960004641 rituximab Drugs 0.000 claims description 4
- 229950006348 sarilumab Drugs 0.000 claims description 4
- 229960003989 tocilizumab Drugs 0.000 claims description 4
- 229960004247 tofacitinib citrate Drugs 0.000 claims description 4
- SYIKUFDOYJFGBQ-YLAFAASESA-N tofacitinib citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 SYIKUFDOYJFGBQ-YLAFAASESA-N 0.000 claims description 4
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 20
- 239000012472 biological sample Substances 0.000 claims 4
- 238000004458 analytical method Methods 0.000 claims 2
- 230000002596 correlated effect Effects 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862644070P | 2018-03-16 | 2018-03-16 | |
| US62/644,070 | 2018-03-16 | ||
| PCT/US2019/022588 WO2019178546A1 (en) | 2018-03-16 | 2019-03-15 | Methods and systems for predicting response to anti-tnf therapies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021518432A JP2021518432A (ja) | 2021-08-02 |
| JPWO2019178546A5 true JPWO2019178546A5 (es) | 2022-02-14 |
| JP7496324B2 JP7496324B2 (ja) | 2024-06-06 |
Family
ID=67907331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020573089A Active JP7496324B2 (ja) | 2018-03-16 | 2019-03-15 | 抗ｔｎｆ療法に対する応答性を予測するための方法及びシステム |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US11198727B2 (es) |
| EP (1) | EP3765634A4 (es) |
| JP (1) | JP7496324B2 (es) |
| WO (1) | WO2019178546A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7496324B2 (ja) | 2018-03-16 | 2024-06-06 | サイファー メディシン コーポレイション | 抗ｔｎｆ療法に対する応答性を予測するための方法及びシステム |
| WO2020264426A1 (en) | 2019-06-27 | 2020-12-30 | Scipher Medicine Corporation | Developing classifiers for stratifying patients |
| KR20230165746A (ko) * | 2020-11-30 | 2023-12-05 | 민데라 코포레이션 | 마이크로니들 디바이스 및 방법, 및 피부 병태 어세이 |
| EP4015651A1 (en) * | 2020-12-17 | 2022-06-22 | Koninklijke Philips N.V. | Treatment prediction and effectiveness of anti-tnf alpha treatment in ibd patients |
| WO2022240875A1 (en) | 2021-05-13 | 2022-11-17 | Scipher Medicine Corporation | Assessing responsiveness to therapy |
| KR20240044417A (ko) * | 2021-06-22 | 2024-04-04 | 사이퍼 메디슨 코퍼레이션 | 개인맞춤형 요법을 위한 방법 및 시스템 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040120952A1 (en) * | 2000-08-07 | 2004-06-24 | Centocor, Inc | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| CA2624359A1 (en) | 2005-09-27 | 2007-04-05 | Source Mdx | Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis |
| US7919264B2 (en) | 2005-11-01 | 2011-04-05 | Abbott Biotechnology Ltd. | Methods and compositions for determining the efficacy of a treatment for ankylosing spondylitis using biomarkers |
| EP2008100A4 (en) | 2006-04-18 | 2009-12-16 | Univ Leland Stanford Junior | ESTABLISHING ANTIBODY PROFILES FOR DETERMINING PATIENT SENSITIVITY TO TREATMENT |
| EP2679996A1 (en) | 2007-05-31 | 2014-01-01 | AbbVie Inc. | Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders |
| JP5719591B2 (ja) | 2007-06-08 | 2015-05-20 | バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． | 抗ｔｎｆ応答性または非応答性を予測するためのバイオマーカー |
| US7863021B2 (en) | 2007-09-05 | 2011-01-04 | Celera Corporation | Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof |
| WO2009102957A2 (en) | 2008-02-14 | 2009-08-20 | The Johns Hopkins University | Methods to connect gene set expression profiles to drug sensitivity |
| WO2009117791A2 (en) * | 2008-03-28 | 2009-10-01 | Katholieke Universiteit Leuven | Mucosal gene signatures |
| ES2445892T3 (es) * | 2008-08-25 | 2014-03-05 | Janssen Biotech, Inc. | Biomarcadores para el tratamiento anti-TNF en colitis ulcerosa y trastornos relacionados |
| US20110191087A1 (en) | 2008-09-03 | 2011-08-04 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Computer implemented model of biological networks |
| CA2737485A1 (en) | 2008-10-10 | 2010-04-15 | Mount Sinai Hospital | Methods for classifying samples based on network modularity |
| WO2011028945A1 (en) | 2009-09-03 | 2011-03-10 | Genentech, Inc. | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
| WO2011047358A1 (en) | 2009-10-15 | 2011-04-21 | Crescendo Bioscience | Biomarkers and methods for measuring and monitoring inflammatory disease activity |
| KR102136041B1 (ko) | 2010-04-29 | 2020-07-20 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 게놈 모델에 대한 데이터 통합을 이용하는 경로 인지 알고리즘 （ｐａｒａｄｉｇｍ） |
| US10192641B2 (en) | 2010-04-29 | 2019-01-29 | The Regents Of The University Of California | Method of generating a dynamic pathway map |
| WO2012066536A2 (en) * | 2010-11-16 | 2012-05-24 | Prediguard | Transcriptome signatures discriminate etanercept-treated rheumatoid arthritis (ra) patients according to their response or refractory status |
| US20130040835A1 (en) * | 2011-05-05 | 2013-02-14 | Exagen Diagnostics, Inc | Genes predictive of anti-TNF response in inflammatory diseases |
| CA2839792A1 (en) | 2011-05-10 | 2012-11-15 | Nestec S.A. | Methods of disease activity profiling for personalized therapy management |
| EP2900695B1 (en) | 2012-09-27 | 2018-01-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
| HU230680B1 (hu) * | 2012-10-19 | 2017-08-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Diagnosztikai eljárás |
| ES2647154T3 (es) | 2012-11-05 | 2017-12-19 | Novigenix Sa | Combinaciones de biomarcadores para tumores colorrectales |
| EP2922861A4 (en) | 2012-11-26 | 2016-09-14 | Caris Life Sciences Switzerland Holdings Gmbh | BIOMARKER COMPOSITIONS AND METHODS |
| WO2014135668A1 (de) | 2013-03-08 | 2014-09-12 | Universität Leipzig | Verfahren und kit zur zytokinanalyse aus einer menschlichen vollblutprobe |
| WO2014186761A2 (en) | 2013-05-17 | 2014-11-20 | The Board Of Trustes Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-cd47 agent |
| WO2015006213A1 (en) | 2013-07-08 | 2015-01-15 | Northeastern University | Methods for identifying complex disease subtypes |
| EP3042202A1 (en) | 2013-09-03 | 2016-07-13 | Graham, L. Douglas | Treatment methods for rheumatoid arthritis |
| WO2015084461A2 (en) | 2013-09-23 | 2015-06-11 | Northeastern University | System and methods for disease module detection |
| CA2943821A1 (en) | 2014-04-02 | 2015-10-08 | Crescendo Bioscience | Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity |
| US9753041B2 (en) | 2014-04-21 | 2017-09-05 | Univeristy Of South Florida | Salivary inflammatory biomarkers associated with glycemic control and oral health |
| CA2964857A1 (en) | 2014-10-20 | 2016-04-28 | Nestec S.A. | Methods for prediction of anti-tnf alpha drug levels and autoantibody formation |
| EP3227685A1 (en) | 2014-12-02 | 2017-10-11 | Nestec S.A. | Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease |
| US10385398B2 (en) | 2015-08-21 | 2019-08-20 | The Children's Hospital Of Philadelphia | Methods for use in combination for the treatment and diagnosis of autoimmune diseases |
| US10018637B2 (en) | 2015-10-06 | 2018-07-10 | Celgene International Ii Sarl | Methods for treating inflammatory and other diseases and the use of biomarkers as predictors of clinical sensitivity to treatment with apremilast |
| EP3165928B1 (en) * | 2015-11-06 | 2019-01-09 | Promise Advanced Proteomics | A method for quantifying anti-tnf antibodies |
| US20190080051A1 (en) | 2015-11-11 | 2019-03-14 | Northeastern University | Methods And Systems For Profiling Personalized Biomarker Expression Perturbations |
| US20170145501A1 (en) * | 2015-11-20 | 2017-05-25 | Lasse Folkersen | Apparatus and methods of using of biomarkers for predicting tnf-inhibitor response |
| WO2017091777A1 (en) * | 2015-11-24 | 2017-06-01 | Vijay Krishnan | Novel healthcare delivery, treatment, and payment model for specialty drugs |
| GB201521357D0 (en) * | 2015-12-03 | 2016-01-20 | Univ Liverpool | Methods for predicting response to anti-TNF therapy |
| JP6572120B2 (ja) | 2015-12-14 | 2019-09-04 | 浜松ホトニクス株式会社 | 光ビーム照射装置 |
| WO2017151755A1 (en) * | 2016-03-02 | 2017-09-08 | Crescendo Bioscience | Biomarkers and methods for predicting response to discontinuation of inflammatory disease therapy |
| WO2017223116A2 (en) | 2016-06-20 | 2017-12-28 | Healthtell Inc. | Methods for differential diagnosis of autoimmune diseases |
| EP3654993A4 (en) | 2017-07-17 | 2021-08-25 | The Broad Institute, Inc. | HUMAN COLON CELL ATLAS IN GOOD HEALTH WITH HEMORRHAGIC RECTO-COLITIS |
| US20200165677A1 (en) | 2017-07-18 | 2020-05-28 | Thaddeus Stappenbeck | Methods and uses of inflammatory bowel disease biomarkers |
| US20190287644A1 (en) | 2018-02-15 | 2019-09-19 | Northeastern University | Correlation Method To Identify Relevant Genes For Personalized Treatment Of Complex Disease |
| JP7496324B2 (ja) | 2018-03-16 | 2024-06-06 | サイファー メディシン コーポレイション | 抗ｔｎｆ療法に対する応答性を予測するための方法及びシステム |
| CA3133639A1 (en) | 2019-03-22 | 2020-10-01 | Inflammatix, Inc. | Systems and methods for deriving and optimizing classifiers from multiple datasets |
| CN114026644A (zh) | 2019-03-28 | 2022-02-08 | 相位基因组学公司 | 通过测序进行核型分析的系统和方法 |
| WO2020264426A1 (en) | 2019-06-27 | 2020-12-30 | Scipher Medicine Corporation | Developing classifiers for stratifying patients |
| MX2023002446A (es) | 2020-09-01 | 2023-05-12 | Scipher Medicine Corp | Metodos y sistemas de prediccion de la respuesta a las terapias anti-tnf. |
| KR20240042361A (ko) | 2021-03-19 | 2024-04-02 | 사이퍼 메디슨 코퍼레이션 | 환자의 분류 및 치료 방법 |
| WO2023150731A2 (en) | 2022-02-04 | 2023-08-10 | Scipher Medicine Corporation | Systems and methods for predicting response to anti-tnf therapies |
-
2019
- 2019-03-15 JP JP2020573089A patent/JP7496324B2/ja active Active
- 2019-03-15 EP EP19768215.6A patent/EP3765634A4/en active Pending
- 2019-03-15 WO PCT/US2019/022588 patent/WO2019178546A1/en unknown
- 2019-04-25 US US16/394,046 patent/US11198727B2/en active Active
-
2021
- 2021-11-02 US US17/517,496 patent/US11987620B2/en active Active
-
2024
- 2024-03-04 US US18/595,176 patent/US20240199729A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jawaheer et al. | Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients | |
| Su et al. | Longitudinal analysis of sarcoidosis blood transcriptomic signatures and disease outcomes | |
| Jonsson et al. | Mutations in collagen, type XVII, alpha 1 (COL17A1) cause epithelial recurrent erosion dystrophy (ERED) | |
| GB2603294A (en) | Developing classifiers for stratifying patients | |
| JP2021503149A (ja) | がん治療の有効性を予測するためのシステムおよび方法 | |
| US11987620B2 (en) | Methods of treating a subject with an alternative to anti-TNF therapy | |
| Curtis et al. | Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year | |
| Salah et al. | MEFV gene mutations and cardiac phenotype in children with familial Mediterranean fever: a cohort study | |
| JP2018506528A5 (es) | ||
| Fonseca et al. | Contribution for new genetic markers of rheumatoid arthritis activity and severity: sequencing of the tumor necrosis factor-alpha gene promoter | |
| Shimizu et al. | Validation of classification criteria of macrophage activation syndrome in Japanese patients with systemic juvenile idiopathic arthritis | |
| JP2015505245A5 (es) | ||
| Ferraz‐Amaro et al. | Coronary artery calcification and rheumatoid arthritis: lack of relationship to risk alleles for coronary artery disease in the general population | |
| Berdeli et al. | Association of macrophage migration inhibitory factor gene− 173 G/C polymorphism with prognosis in turkish children with juvenile rheumatoid arthritis | |
| GB2622147A (en) | Methods of classifying and treating patients | |
| Richard et al. | Biomarkers of kidney function and cognitive ability: A Mendelian randomization study | |
| JPWO2019178546A5 (es) | ||
| JPWO2020264426A5 (es) | ||
| Lau et al. | THU0153 pregnancy outcomes in women exposed to the tumor necrosis factor inhibitor, golimumab | |
| WO2022266302A1 (en) | Systems and methods for improved targeted therapy | |
| CN114324887A (zh) | 免疫球蛋白a肾病t细胞诊断标志物 | |
| CA2662282A1 (en) | A pharmacogenetic method for prediction of the efficacy of methotrexate monotherapy in recent-onset arthritis | |
| Blundell et al. | Which Biologic Therapies to Treat Active Rheumatoid Arthritis and When? | |
| Adang et al. | IFN-signaling gene expression as a diagnostic biomarker for monogenic interferonopathies | |
| Seddon et al. | Association between Drusen Burden Determined by OCT and Genetic Risk in Early and Intermediate Age-Related Macular Degeneration |